Cardiomyopathy Trial, Recruiting NCT07398950 Sponsor: Yale University Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT07398950
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have had at least one ECG (a heart rhythm test) and one echocardiogram (a heart ultrasound) recorded within the Yale New Haven Health System
  • People who have been diagnosed with a type of heart failure known as HFpEF or HFmrEF (heart failure where the heart muscle stiffens or has mildly reduced pumping ability)
  • People who took part in the Phase I TRACE-AI Study and had AI-assisted ECG and echocardiogram screening within the past 36 months

Who may not be able to join:

  • People who have previously chosen to opt out of research studies
  • People who have had testing for cardiac amyloid (a specific heart condition involving protein buildup) within the past 36 months
  • People who have been diagnosed with hypertrophic cardiomyopathy (a thickened heart muscle condition) or end-stage kidney disease
  • People who are pregnant
  • People who are unable or unwilling to give their informed consent to participate
  • People who do not speak English, or people with cognitive difficulties that would make it hard to understand the consent forms and on-screen instructions, which are provided in English only

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rohan Khera, MD, MS, Yale University

Phone: 203-764-5885

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
31 July 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Performance of the sequential screening approach

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov